Literature DB >> 19735079

Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.

Carsten Berges1, Heinrich Haberstock, Dominik Fuchs, Mahmoud Sadeghi, Gerhard Opelz, Volker Daniel, Cord Naujokat.   

Abstract

We have previously shown that inhibition of the proteolytic activity of the proteasome induces apoptosis and suppresses essential functions of activated human CD4(+) T cells, and we report now the detailed mechanisms of apoptosis following proteasome inhibition in these cells. Here we show that proteasome inhibition by bortezomib activates the mitochondrial pathway of apoptosis in activated CD4(+) T cells by disrupting the equilibrium of pro-apoptotic and anti-apoptotic proteins at the outer mitochondrial membrane (OMM) and by inducing the generation of reactive oxygen species (ROS). Proteasome inhibition leads to accumulation of pro-apoptotic proteins PUMA, Noxa, Bim and p53 at the OMM. This event provokes mitochondrial translocation of activated Bax and Bak homodimers, which induce loss of mitochondrial membrane potential (DeltaPsim). Breakdown of DeltaPsim is followed by rapid release of pro-apoptotic Smac/DIABLO and HtrA2 from mitochondria, whereas release of cytochrome c and AIF is delayed. Cytoplasmic Smac/DIABLO and HtrA2 antagonize IAP-mediated inhibition of partially activated caspases, leading to premature activation of caspase-3 followed by activation of caspase-9. Our data show that proteasome inhibition triggers the mitochondrial pathway of apoptosis by activating mutually independent apoptotic pathways. These results provide novel insights into the mechanisms of apoptosis induced by proteasome inhibition in activated T cells and underscore the future use of proteasome inhibitors for immunosuppression. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735079     DOI: 10.1002/jcb.22325

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.

Authors:  Stefanie Geisler; Ryan A Doan; Galen C Cheng; Aysel Cetinkaya-Fisgin; Shay X Huang; Ahmet Höke; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  JCI Insight       Date:  2019-09-05

2.  Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.

Authors:  Mari Hashimoto; Yoriko Saito; Ryo Nakagawa; Ikuko Ogahara; Shinsuke Takagi; Sadaaki Takata; Hanae Amitani; Mikiko Endo; Hitomi Yuki; Jordan A Ramilowski; Jessica Severin; Ri-Ichiroh Manabe; Takashi Watanabe; Kokoro Ozaki; Akiko Kaneko; Hiroshi Kajita; Saera Fujiki; Kaori Sato; Teruki Honma; Naoyuki Uchida; Takehiro Fukami; Yasushi Okazaki; Osamu Ohara; Leonard D Shultz; Makoto Yamada; Shuichi Taniguchi; Paresh Vyas; Michiel de Hoon; Yukihide Momozawa; Fumihiko Ishikawa
Journal:  Nat Cancer       Date:  2021-03-18

Review 3.  The discovery of novel experimental therapies for inflammatory arthritis.

Authors:  Charles J Malemud
Journal:  Mediators Inflamm       Date:  2010-03-18       Impact factor: 4.711

Review 4.  Immediate early response gene X-1, a potential prognostic biomarker in cancers.

Authors:  Mei X Wu; Irina V Ustyugova; Liping Han; Oleg E Akilov
Journal:  Expert Opin Ther Targets       Date:  2013-02-04       Impact factor: 6.902

Review 5.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

6.  A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.

Authors:  L Hernandez; M K Kim; A M Noonan; E Sagher; H Kohlhammer; G Wright; L T Lyle; P S Steeg; M Anver; D D Bowtell; C M Annunziata
Journal:  Cell Death Discov       Date:  2015-12-14

7.  Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.

Authors:  Xin Du; Jia Tong; Hongying Lu; Cong He; Shenghong Du; Peimin Jia; Weili Zhao; Hanzhang Xu; Junmin Li; Zhixiang Shen; Yingli Wu; Jianhua Tong; Li Zhou
Journal:  Mol Med Rep       Date:  2017-05-09       Impact factor: 2.952

Review 8.  Protein synthesis, degradation, and energy metabolism in T cell immunity.

Authors:  Julia M Marchingo; Doreen A Cantrell
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 22.096

9.  ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines.

Authors:  Yi Xie; Bing Wang; Liqing Du; Yan Wang; Chang Xu; Hong Zhang; Kaixue Wen; Qiang Liu; Takanori Katsube
Journal:  Cancer Biol Med       Date:  2021-09-21       Impact factor: 5.347

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.